Abstract
ABSTRACT Lipid nanoparticle (LNP) technology is critical to the advancement of mRNA vaccines. However, most studies focus on technical aspects and neglect the patent landscape. Moreover, there is a lack of differentiation of LNP technology differences among mRNA, mRNA vaccines, and COVID-19 mRNA vaccines, leading to confusing comparisons. This study fills this gap by analyzing LNP technology in academic journals and patents for mRNA, mRNA vaccines, and COVID-19 mRNA vaccines. The results show (1) academic impact on journal articles and patents, but no direct positive correlation; (2) the USA leads in academic research and patents, with China following closely; and (3) many cited articles have sponsors, indicating the importance of industry-university collaboration. This research aids strategic planning in government, academia, and industry, by providing trend analysis of LNP technology in journals and patents.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
